PREDICT Validity for Prognosis of Breast Cancer Patients With Pathogenic BRCA1/2 Variants

Janssen Presents First-ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Trial of KN046, a Novel Bispecific Antibody Targeting PD-L1 and CTLA-4 in Patients With Advanced Solid Tumors

HD201 Comparable to Referent Trastuzumab for HER2-Positive Breast Cancer

Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

IMscin001 Part 2: A Randomised Phase 3, Open-label, Multicentre Study Examining the Pharmacokinetics, Efficacy, Immunogenicity, and Safety of Atezolizumab Subcutaneous versus Intravenous in Previously Treated Locally Advanced or Metastatic NSCLC

Menstrual Suppression in the Myelosuppressed: A Retrospective Cohort Study

Camrelizumab Plus Apatinib and Temozolomide as First-line Treatment in Patients With Advanced Acral Melanoma

PREDICT Validity for Prognosis of Breast Cancer Patients With Pathogenic BRCA1/2 Variants

header-info

May, 15, 2023

Further analysis of PREDICT v 2.2 in a cohort of 5,453 BRCA1/2 carriers indicated that analysis of BRCA2 status should be included alongside tumor characterization when estimating prognosis in patients with ER+ breast cancer.

Access the full article to read more here.